biostudies-literatureUnknown8(5)Zelniker TA<h4>Importance</h4>Dapagliflozin reduces the risk of hospitalizations for heart failure and the progression of chronic kidney disease in patients with and without type 2 diabetes (T2D), whereas the effects on reducing atherosclerotic events appear less clear.<h4>Objective</h4>To explore whether N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hsTnT) levels can identify a subset of patients with T2D at higher risk and who might benefit more from dapagliflozin with regard to atherosclerotic events.<h4>Design, setting, and participants</h4>This was a secondary analysis of the DECLARE-TIMI 58 trial, a randomized clinical trial of dapagliflozin in patients with T2D and either multiple risk factors for atherosclerotic cardiovascular disease (ASCVD; aJAMA cardiology503-509https://www.ebi.ac.uk/biostudies/studies/S-EPMC9979005biostudies-literatureAssociation of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial.PMC9979005Jarolim PRaz IWiviott SDLangkilde AMBudaj AMorrow DAGause-Nilsson IRay KKMosenzon OLeiter LAGoodrich ELMcGuire DKParkhomenko ASabatine MSZelniker TACahn AFredriksson MBhatt DLWilding JAverkov OfalseAssociation of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial.<h4>Importance</h4>Dapagliflozin reduces the risk of hospitalizations for heart failure and the progression of chronic kidney disease in patients with and without type 2 diabetes (T2D), whereas the effects on reducing atherosclerotic events appear less clear.<h4>Objective</h4>To explore whether N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hsTnT) levels can identify a subset of patients with T2D at higher risk and who might benefit more from dapagliflozin with regard to atherosclerotic events.<h4>Design, setting, and participants</h4>This was a secondary analysis of the DECLARE-TIMI 58 trial, a randomized clinical trial of dapagliflozin in patients with T2D and either multiple risk factors for atherosclerotic cardiovascular disease (ASCVD; a2023-01-01T00:00:00Z2023 May2026-06-01T17:22:28.805Z2025-04-04T20:40:41.24ZS-EPMC99790053685703510.1001/jamacardio.2023.0019